Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IKZF1/IKZF3 protein degrader GLB-002

An orally bioavailable protein degrader of the transcription factors Ikaros (Ikaros family zinc finger protein 1; IKZF1) and Aiolos (Ikaros family zinc finger protein 3; IKZF3), with potential immunomodulating and antineoplastic activities. Upon oral administration, IKZF1/IKZF3 protein degrader GLB-002 modulates the E3 (ubiquitin) ligase and targets IKZF1 and IKZF3 for ubiquitination, and induces proteasome-mediated degradation of IKZF1 and IKZF3. This reduces the levels of these transcription factors, which are transcriptional repressors in T cells, and modulates the activity of the immune system. This also leads to the downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which may result in apoptosis and the inhibition of tumor cell proliferation. IKZF1 and IKZF3 play a key role in B- and T-cell differentiation. IRF4, overexpressed in certain malignancies, is a transcription factor and key regulator of multiple genes controlling tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Ikaros/Aiolos protein degrader GLB-002
IKZF1/3 molecular glue protein degrader GLB-002
IKZF1/3 protein degrader GLB-002
Code name:GLB 002
GLB-002
GLB-A062-B
GLB002
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search